Background The treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis (TEN) with
high-dose intravenous immunoglobulin (IVIg) is a well-established procedure in dermatology. As treatment with IVIg is
usually considered for rare clinical entities or severe clinical cases, the use of immunoglobulin is not generally based on
data from randomized controlled trials that are usually required for the practice of evidence-based medicine. Owing to
the rarity of the indications for the use of IVIg, it is also unlikely that such studies will be available in the foreseeable
future. Because the high costs of IVIg treatment also limit itsfirst-line use, thefirst clinical guidelines on its use in dermatological conditions were established in 2008 and renewed in 2011.
Materials and methodsThe European guidelines presented here were prepared by a panel of experts nominated by
the EDF and the EADV. The guidelines were developed to update the indications for treatment currently considered as
effective and to summarize the evidence base for the use of IVIg in dermatological autoimmune diseases and TEN.
Results and conclusion The current guidelines represent consensual expert opinions and definitions on the use of
IVIg reflecting current published evidence and are intended to serve as a decision-making tool for the use of IVIg in dermatological diseases.
Received: 22 October 2015; Accepted: 9 February 2016
Conflicts of interest
Conflicts of interest statement presented in the appendix.